This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Amedisys motion to separate Section 7A claim should be denied, US DOJ says

( March 4, 2025, 23:28 GMT | Official Statement) -- MLex Summary: The US Justice Department, in its lawsuit to halt the Amedisys merger with UnitedHealth, argued against an Amedisys motion seeking to separate counts involving the merger review and the potential relief. The company said the Section 7 merger review is distinct from the Section 7A claim that seeks a monetary penalty, while the agency said arguing the counts separately would "wreak significant inefficiency, squander the Court’s time with two discovery periods and trials, and generate needless expense and delay."See attached document....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login